Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
lennox gastaut syndrome market insight epidemiology and market forecast

SALE

Lennox Gastaut Syndrome - Market Insight, Epidemiology and Market Forecast - 2028

Published Date : 2019

Pages : 120

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

lennox gastaut syndrome market insight epidemiology and market forecast

DelveInsight's 'Lennox Gastaut Syndrome - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Lennox Gastaut Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Lennox Gastaut Syndrome from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2017-2028

Lennox Gastaut Syndrome - Disease Understanding and Treatment Algorithm

The DelveInsight Lennox Gastaut Syndrome market report gives the thorough understanding of the Lennox Gastaut Syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Lennox Gastaut Syndrome in the US, Europe, and Japan.

Lennox Gastaut Syndrome Epidemiology

The Lennox Gastaut Syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

According to DelveInsight, the prevalent cases of Lennox Gastaut Syndrome was 68,562 in 2017 in 7 MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2017-2028. Among 7MM, United States account for highest prevalent cases of Lennox Gastaut Syndrome with 31,772 prevalent cases in 2017. In 7MM, males had highest prevalent cases of LGS as compared to females in 2017. This trend is expected to increase during the study period

Lennox Gastaut Syndrome Drug Chapters

This segment of the Lennox Gastaut Syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently, there are 7 drugs approved in market for Lennox Gastaut Syndrome along with other off-label therapies. This report includes detailed chapters of marketed along with the promising upcoming therapies.

Lennox Gastaut Syndrome Market Outlook

The Lennox Gastaut Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Lennox Gastaut Syndrome market is expected to grow during the forecasted period of 2018-2028 at a CAGR of XX% owing to the launch of three drugs (presently in Phase III and Phase II). Lennox Gastaut Syndrome Therapeutics market has seen a 7MM sales of USD 1356.4 million in 2017. The approved medications are Epidiolex (GW PHarma), Topamax (Jansenn Pharmaceuticals), Banzel (Jansenn Pharmaceuticals) , Lamictal (GlaxoSmithKline), Felbatol (Meda Pharmaceuticals), Onfi (Lundbeck) and Klonopin (Roche)

Lennox Gastaut Syndrome Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Lennox Gastaut Syndrome Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Lennox Gastaut Syndrome Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Lennox Gastaut Syndrome Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Lennox Gastaut Syndrome market

• Organize sales and marketing efforts by identifying the best opportunities for Lennox Gastaut Syndrome market

• To understand the future market competition in the Lennox Gastaut Syndrome market.

1. Key Insights

2. Lennox Gastaut Syndrome (LGS) Market Overview at a Glance

2.1. Market Share (%) Distribution of LGS in 2018

2.2. Market Share (%) Distribution of LGS in 2028

3. Disease Overview: Lennox Gastaut Syndrome (LGS)

3.1. Introduction

3.2. Classification

3.3. Signs and Symptoms

3.4. Types of Seizures associated with LGS

3.5. Etiology

3.6. Pathogenesis

3.7. Diagnosis

3.7.1. Differential Diagnosis

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. 7MM Total Diagnosed Prevalent Patient Population of Lennox Gastaut Syndrome (LGS)

4.3. Country Wise-Epidemiology of Lennox Gastaut Syndrome (LGS)

4.4. United States

4.4.1. Assumptions and Rationale

4.4.2. Diagnosed Prevalent Cases of Lennox Gastaut Syndrome in the United States

4.4.3. Gender-specific Diagnosed Prevalent Cases of LGS in the US

4.4.4. Seizure-specific Diagnosed Prevalent Cases of LGS in the US

4.5. Germany

4.5.1. Assumptions and Rationale

4.5.2. Diagnosed Prevalent Cases of LGS in Germany

4.5.3. Gender-specific Diagnosed Prevalent Cases of LGS in Germany

4.5.4. Seizure-specific Diagnosed Prevalent Cases of LGS in Germany

4.6. France

4.6.1. Assumptions and Rationale

4.6.2. Diagnosed Prevalent Cases of LGS in France

4.6.3. Gender-specific Diagnosed Prevalent Cases of LGS in France

4.6.4. Seizure-specific Diagnosed Prevalent Cases of LGS in France

4.7. Italy

4.7.1. Assumptions and Rationale

4.7.2. Diagnosed Prevalent Cases of LGS in Italy

4.7.3. Gender-specific Diagnosed Prevalent Cases of LGS in Italy

4.7.4. Seizure-specific Diagnosed Prevalent Cases of LGS in Italy

4.8. Spain

4.8.1. Assumptions and Rationale

4.8.2. Diagnosed Prevalent Cases of LGS in Spain

4.8.3. Gender-specific Diagnosed Prevalent Cases of LGS in Spain

4.8.4. Seizure-specific Diagnosed Prevalent Cases of LGS in Spain

4.9. United Kingdom

4.9.1. Assumptions and Rationale

4.9.2. Diagnosed Prevalent Cases of LGS in the United Kingdom

4.9.3. Gender-specific Diagnosed Prevalent Cases of LGS in the United Kingdom

4.9.4. Seizure-specific Diagnosed Prevalent Cases of LGS in the United Kingdom

4.10. Japan

4.10.1. Assumptions and Rationale

4.10.2. Diagnosed Prevalent Cases of LGS in Japan

4.10.3. Gender-specific Diagnosed Prevalent Cases of LGS in Japan

4.10.4. Seizure-specific Diagnosed Prevalent Cases of LGS in Japan

5. Current Treatment Practices

5.1. Treatment Algorithm

5.2. Treatment Guidelines

5.2.1. NICE Guidelines

5.2.2. American Academy of Neurology (AAN)

6. Unmet needs

7. Marketed drugs

7.1. Lamictal: GlaxoSmithKline

7.1.1. Drug Description

7.1.2. Mechanism of Action

7.1.3. Regulatory Milestones

7.1.4. Safety and Efficacy

7.1.5. Product Profile

7.2. Felbatol: Meda Pharmaceuticals

7.2.1. Drug Description

7.2.2. Mechanism of Action

7.2.3. Product Developmental Activities

7.2.4. Safety and Efficacy

7.2.5. Product Profile

7.3. Klonopin: Roche

7.3.1. Drug Description

7.3.2. Mechanism of Action

7.3.3. Regulatory Milestones

7.4. Onfi: Lundbeck

7.4.1. Drug Description

7.4.2. Mechanism of Action

7.4.3. Regulatory Milestones

7.4.4. Product Developmental Activities

7.4.5. Safety and Efficacy

7.4.6. Product Profile

7.5. Epidiolex: Greenwich Biosciences

7.5.1. Drug Description

7.5.2. Mechanism of Action

7.5.3. Regulatory Milestones

7.5.4. Clinical Trials

7.5.5. Safety and Efficacy

7.5.6. Product Profile

7.6. Banzel: Janssen Pharmaceuticals

7.6.1. Drug Description

7.6.2. Mechanism of action

7.6.3. Regulatory Milestones

7.6.4. Advantages & Disadvantages

7.6.5. Clinical Trials

7.6.6. Safety and Efficacy

7.6.7. Product Profile

7.7. Topamax: Janssen Pharmaceuticals

7.7.1. Product Description

7.7.2. Mechanism of Action

7.7.3. Regulatory Milestones

7.7.4. Clinical Trials

7.7.5. Safety and Efficacy

7.7.6. Product Profile

8. Emerging Therapies

8.1. Key cross competition- Emerging Therapies

8.2. Phase-III Drugs

8.3. Fycompa: Eisai

8.3.1. Product Description

8.3.2. Other Developmental Activities

8.3.3. Clinical Development

8.3.4. Safety and Efficacy

8.3.5. Advantages and Disadvantages

8.3.6. Product Profile

8.4. ZX 008: Zogenix International Limited, Inc., a subsidiary of Zogenix

8.4.1. Product Description

8.4.2. Other Developmental Activities

8.4.3. Clinical Development

8.4.4. Safety and Efficacy

8.4.5. Advantages and Disadvantages

8.4.6. Product Profile

8.5. Phase-II Drugs

8.6. TAK-935/ OV935: Takeda/Ovid

8.6.1. Product Description

8.6.2. Other Developmental Activities

8.6.3. Clinical Development

8.6.4. Safety and Efficacy

8.6.5. Product Profile

9. Lennox Gastaut Syndrome: 7 Major Market Analysis

9.1. Key Findings

9.2. Market Size of Lennox Gastaut Syndrome (LGS) in 7MM

10. Market Outlook by Country

11. The United States: Market Outlook

11.1. United States Market Size

11.1.1. Total Market size of LGS

11.1.2. Therapy Based Market Size of LGS in the US

12. EU-5 Countries: Market Outlook

12.1. Germany

12.1.1. Total Market size of LGS

12.1.2. Therapy Based Market Size of LGS in Germany

12.2. France

12.2.1. Total Market size of LGS

12.2.2. Therapy Based Market Size of LGS in France

12.3. Italy

12.3.1. Total Market size of LGS in Italy

12.3.2. Therapy Based Market Size of LGS in Italy

12.4. Spain

12.4.1. Total Market size of LGS in Spain

12.4.2. Therapy Based Market Size of LGS in Spain

12.5. United Kingdom

12.5.1. Total Market size of LGS in the United Kingdom

12.5.2. Therapy Based Market Size of LGS in the UK

12.6. Japan: Market Outlook

12.6.1. Total Market size of LGS in Japan

12.6.2. Therapy Based Market Size of LGS in Japan

13. Market Drivers

14. Market Barriers

15. Appendix

15.1. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

List of Tables:

Table 1: Diagnosed Prevalent Patient Population of LGS in 7MM (2017-2028)

Table 2: Diagnosed Prevalent Cases of LGS in the United States (2017-2028)

Table 3: Gender-specific Diagnosed Prevalent Cases of LGS in the United States (2017-2028)

Table 4: Seizure-specific Diagnosed Prevalent Cases of LGS in the United States (2017-2028)

Table 5: Diagnosed Prevalent Cases of LGS in Germany (2017-2028)

Table 6: Gender-specific Diagnosed Prevalent Cases of LGS in Germany (2017-2028)

Table 7: Seizure-specific Diagnosed Prevalent Cases of LGS in Germany (2017-2028)

Table 8: Diagnosed Prevalent Cases of LGS in France (2017-2028)

Table 9: Gender-specific Diagnosed Prevalent Cases of LGS in France (2017-2028)

Table 10: Seizure-specific Diagnosed Prevalent Cases of LGS in France (2017-2028)

Table 11: Diagnosed Prevalent Cases of LGS in Italy (2017-2028)

Table 12: Gender-specific Diagnosed Prevalent Cases of LGS in Italy (2017-2028)

Table 13: Seizure-specific Diagnosed Prevalent Cases of LGS in Italy (2017-2028)

Table 14: Diagnosed Prevalent Cases of LGS in Spain (2017-2028)

Table 15: Gender-specific Diagnosed Prevalent Cases of LGS in Spain (2017-2028)

Table 16: Seizure-specific Diagnosed Prevalent Cases of LGS in Spain (2017-2028)

Table 17: Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2028)

Table 18: Gender-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2028)

Table 19: Seizure-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2028)

Table 20: Diagnosed Prevalent Cases of LGS in Japan (2017-2028)

Table 21: Gender-specific Diagnosed Prevalent Cases of LGS in Japan (2017-2028)

Table 22: Seizure-specific Diagnosed Prevalent Cases of LGS in Japan (2017-2028)

List of Figures:

Figure 1: Diagnosed Prevalent Patient Population of LGS in 7MM (2017-2028)

Figure 2: Diagnosed Prevalent Cases of LGS in the United States (2017-2028)

Figure 3: Gender-specific Diagnosed Prevalent Cases of LGS in the United States (2017-2028)

Figure 4: Seizure-specific Diagnosed Prevalent Cases of LGS in the United States (2017-2028)

Figure 5: Diagnosed Prevalent Cases of LGS in Germany (2017-2028)

Figure 6: Gender-specific Diagnosed Prevalent Cases of LGS in Germany (2017-2028)

Figure 7: Seizure-specific Diagnosed Prevalent Cases of LGS in Germany (2017-2028)

Figure 8: Diagnosed Prevalent Cases of LGS in France (2017-2028)

Figure 9: Gender-specific Diagnosed Prevalent Cases of LGS in France (2017-2028)

Figure 10: Seizure-specific Diagnosed Prevalent Cases of LGS in France (2017-2028)

Figure 11: Diagnosed Prevalent Cases of LGS in Italy (2017-2028)

Figure 12: Gender-specific Diagnosed Prevalent Cases of LGS in Italy (2017-2028)

Figure 13: Seizure-specific Diagnosed Prevalent Cases of LGS in Italy (2017-2028)

Figure 14: Diagnosed Prevalent Cases of LGS in Spain (2017-2028)

Figure 15: Gender-specific Diagnosed Prevalent Cases of LGS in Spain (2017-2028)

Figure 16: Seizure-specific Diagnosed Prevalent Cases of LGS in Spain (2017-2028)

Figure 17: Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2028)

Figure 18: Gender-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2028)

Figure 19: Seizure-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2028)

Figure 20: Diagnosed Prevalent Cases of LGS in Japan (2017-2028)

Figure 21: Gender-specific Diagnosed Prevalent Cases of LGS in Japan (2017-2028)

Figure 22: Seizure-specific Diagnosed Prevalent Cases of LGS in Japan (2017-2028)

Figure 23: Unmet needs for LGS

Figure 24: 7 Major Market Size of LGS in USD Million (2017-2028)

Figure 25: Market Size of LGS in the United States, USD Millions (2017-2028)

Figure 26: Therapy Based Market Size of LGS in the US in USD Million (2017-2028)

Figure 27: Market Size of LGS in Germany, USD Millions (2017-2028)

Figure 28: Therapy Based Market Size of LGS in Germany in USD Million (2017-2028)

Figure 29: Market Size of LGS in France USD Millions (2017-2028)

Figure 30: Therapy Based Market Size of LGS in France in USD Million (2017-2028)

Figure 31: Market Size of LGS in Italy, USD Millions (2017-2028)

Figure 32: Therapy Based Market Size of LGS in Italy in USD Million (2017-2028)

Figure 33: Market Size of LGS in Spain, USD Millions (2017-2028)

Figure 34: Therapy Based Market Size of LGS in Spain in USD Million (2017-2028)

Figure 35: Market Size of LGS in the United Kingdom, USD Millions (2017-2028)

Figure 36: Therapy Based Market Size of LGS in the United Kingdom in USD Million (2017-2028)

Figure 37: Market Size of LGS in Japan, USD Millions (2017-2028)

Figure 38: Therapy Based Market Size of LGS in Japan in USD Million (2017-2028)

Figure 39: Market Drivers

Figure 40: Market Barriers

Tags:

License Type

Offer